0000000000549713

AUTHOR

Barbara Jarzab

showing 6 related works from this author

Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants

2015

et al.

Maleendocrine system diseasesEndocrinology Diabetes and MetabolismClinical BiochemistryPapillaryAdult; Carcinoma; Carcinoma Papillary; Cohort Studies; Female; Follow-Up Studies; Gene Frequency; Humans; Male; Middle Aged; Neoplasm Metastasis; Prevalence; Prognosis; Radiotherapy; Retrospective Studies; Risk Assessment; Thyroid Cancer Papillary; Thyroid Neoplasms; Neoplasm Recurrence LocalThyroid CancerBiochemistryPapillary thyroid cancerCohort StudiesThyroid carcinoma Papillary Thyroid Carcinoma Variants Prognosis0302 clinical medicineEndocrinologyGene FrequencyInterquartile rangePrevalenceNeoplasm MetastasisMiddle AgedPrognosisDiabetes and MetabolismLocalThyroid Cancer Papillary030220 oncology & carcinogenesisFemaleCohort studyAdultmedicine.medical_specialtyBiochemistry; Clinical Biochemistry; Endocrinology; Biochemistry (medical); Endocrinology Diabetes and Metabolism030209 endocrinology & metabolismContext (language use)Risk AssessmentThyroid carcinoma03 medical and health sciencesInternal medicinemedicineCarcinomaHumansThyroid NeoplasmsRetrospective StudiesRadiotherapybusiness.industryBiochemistry (medical)CarcinomaCancerRetrospective cohort studyOriginal Articlesmedicine.diseaseCarcinoma PapillaryEndocrinologyNeoplasm RecurrenceNeoplasm Recurrence LocalbusinessFollow-Up Studies
researchProduct

Differential miRNA expression defines migration and reduced apoptosis in follicular thyroid carcinomas.

2013

The objective of the study was to identify microRNAs (miRs) characteristic for follicular thyroid carcinoma (FTC) and to define their role in tumorigenesis. A miR-microarray study was conducted to identify miRs differentially expressed between FTCs and their surrounding tissues. Selection was further reinforced by a literature review. Four miRs were selected and confirmed by RT-qPCR: miR-146b, -183, -221 were up-regulated, whereas miR-199b down-regulated in FTCs. The influence of these miRs on cell proliferation, cell cycle, apoptosis and migration was studied in HTori and FTC-133 cells. Functional characterization suggests an impact of miR-183 and miR-146b in FTC development. Overexpressio…

medicine.medical_specialtyApoptosisBiologymedicine.disease_causeBiochemistryThyroid carcinomaEndocrinologyCell MovementInternal medicineCell Line TumorFollicular phasemicroRNAAdenocarcinoma FollicularmedicineHumansThyroid NeoplasmsFollicular thyroid cancerMolecular BiologyCell ProliferationCell growthCell cyclemedicine.diseaseGene Expression Regulation NeoplasticMicroRNAsEndocrinologyApoptosisCancer researchCarcinogenesisMolecular and cellular endocrinology
researchProduct

A multicenter, randomized, blinded, phase III study of pasireotide LAR versus octreotide LAR in patients with metastatic neuroendocrine tumors (NET) …

2013

4031 Background: The novel somatostatin analog (SSA) pasireotide has a broader binding profile than currently available SSA (octreotide and lanreotide). Results from a phase III study (NCT00690430) of pasireotide LAR (P) vs octreotide LAR (O) in patients (pts) with NET and disease-related symptoms uncontrolled by the maximum approved dose of available SSA are shown. Methods: Pts (N=110) were randomized and stratified by predominant symptom at baseline (diarrhea [D], flushing [F], or D+F) 1:1 to P (60 mg IM) or O (40 mg IM) q28d. Primary objective was symptom response at month (M) 6. Secondary objectives included tumor response and safety. Progression-free survival (PFS) was an exploratory …

Cancer Researchmedicine.medical_specialtybusiness.industryOctreotideDiseaseNeuroendocrine tumorsmedicine.diseaseLanreotideOctreotide larGastroenterologyPasireotidechemistry.chemical_compoundSomatostatinEndocrinologyOncologychemistryInternal medicineMedicineIn patientbusinessmedicine.drugJournal of Clinical Oncology
researchProduct

Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available s…

2015

Edward M Wolin,1 Barbara Jarzab,2 Barbro Eriksson,3 Thomas Walter,4 Christos Toumpanakis,5 Michael A Morse,6 Paola Tomassetti,7 Matthias M Weber,8 David R Fogelman,9 John Ramage,10 Donald Poon,11 Brian Gadbaw,12 Jiang Li,12 Janice L Pasieka,13 Abakar Mahamat,14 Fredrik Swahn,15 John Newell-Price,16 Wasat Mansoor,17 Kjell Öberg3 1Markey Cancer Center, University of Kentucky, Lexington, KY, USA; 2Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland; 3Department of Medical Sciences, Endocrine Oncology Unit, University Hospital, Uppsala, Sweden; 4Department of Medical Oncology, Ed…

MaleTime FactorsPharmaceutical ScienceOctreotideKaplan-Meier EstimateNeuroendocrine tumorsDigestive System NeoplasmsOctreotideGastroenterologychemistry.chemical_compoundDrug DiscoveryOdds RatioOriginal ResearchAged 80 and oversomatostatin analoguesDrug SubstitutionHazard ratioMiddle AgedTumor BurdenTreatment OutcomeFemalemedicine.symptomSomatostatinCarcinoid syndromemedicine.drugAdultmedicine.medical_specialtyNauseaCarcinoid tumorscarcinoid syndromeAntineoplastic AgentsCarcinoid TumorDisease-Free SurvivalDouble-Blind MethodInternal medicinemedicineHumansProgression-free survivalAgedProportional Hazards ModelsPharmacologypasireotideCancer och onkologiDrug Design Development and Therapybusiness.industrylcsh:RM1-950medicine.diseasesymptom controlPasireotidelcsh:Therapeutics. PharmacologyEndocrinologyLogistic ModelschemistryDrug Resistance NeoplasmDelayed-Action PreparationsCancer and Oncologyneuroendocrine tumorsbusinessprogression-free survival
researchProduct

Gene Expression (mRNA) Markers for Differentiating between Malignant and Benign Follicular Thyroid Tumours

2017

Distinguishing between follicular thyroid cancer (FTC) and follicular thyroid adenoma (FTA) constitutes a long-standing diagnostic problem resulting in equivocal histopathological diagnoses. There is therefore a need for additional molecular markers. To identify molecular differences between FTC and FTA, we analyzed the gene expression microarray data of 52 follicular neoplasms. We also performed a meta-analysis involving 14 studies employing high throughput methods (365 follicular neoplasms analyzed). Based on these two analyses, we selected 18 genes differentially expressed between FTA and FTC. We validated them by quantitative real-time polymerase chain reaction (qRT-PCR) in an independe…

0301 basic medicinePathologyMicroarrayThyroid Glandlaw.inventionlawFollicular phaseGene expressionAdenocarcinoma Follicularfollicular thyroid adenoma; follicular thyroid cancer; gene expression; microarray; meta-analysisSpectroscopyPolymerase chain reactionOligonucleotide Array Sequence Analysisfollicular thyroid cancerGeneral MedicineCANCERComputer Science ApplicationsGene Expression Regulation NeoplasticCARCINOMASFUSION ONCOGENEmicroarrayNEOPLASMSmedicine.medical_specialtyMOLECULAR MARKERSASPIRATIONBiologyCatalysisCLASSIFICATIONArticleInorganic Chemistry03 medical and health sciencesNODULESADENOMASmedicineBiomarkers TumorHumansRNA MessengerThyroid NeoplasmsPhysical and Theoretical ChemistryFollicular thyroid cancerMolecular BiologyGeneGene Expression ProfilingOrganic ChemistryThyroid adenomaACVRL1medicine.diseaseMODELmeta-analysis030104 developmental biologyfollicular thyroid adenomaMutationgene expressionInternational Journal of Molecular Sciences
researchProduct

European Thyroid Association Guidelines regarding Thyroid Nodule Molecular Fine-Needle Aspiration Cytology Diagnostics

2016

Molecular fine-needle aspiration (FNA) cytology diagnostics has the potential to address the inherent limitation of FNA cytology which is an indeterminate (atypia of undetermined significance/follicular lesion of undetermined significance follicular neoplasm) cytology. Because of the emerging role of molecular FNA cytology diagnostics, the European Thyroid Association convened a panel of international experts to review methodological aspects, indications, results, and limitations of molecular FNA cytology diagnostics. The panel reviewed the evidence for the diagnostic value of mutation panel assessment (including at least BRAF, NRAS, HRAS, KRAS, PAX8/PPARG, RET/PTC) of targeted next generat…

Neuroblastoma RAS viral oncogene homologOncologyThyroid nodulesmedicine.medical_specialtyPathologyendocrine system diseasesEndocrinology Diabetes and MetabolismEuropean Thyroid Association; Fine-needle aspiration; Thyroid030209 endocrinology & metabolismGuidelinesmedicine.disease_cause03 medical and health sciences0302 clinical medicineEuropean Thyroid AssociationCytologyInternal medicineAtypiaMedicineskin and connective tissue diseasesneoplasmsFine-needle aspirationThyroidmedicine.diagnostic_testbusiness.industryThyroidmedicine.diseasemedicine.anatomical_structureFine-needle aspiration030220 oncology & carcinogenesisKRASbusinessPAX8
researchProduct